Suppr超能文献

在泰国,与透析后肾移植相比,抢先进行的亲属活体肾移植是一种节省成本的策略。

Preemptive Living-Related Kidney Transplantation Is a Cost-Saving Strategy Compared With Post-dialysis Kidney Transplantation in Thailand.

作者信息

Phongphithakchai Atthaphong, Phisalprapa Pochamana, Kositamongkol Chayanis, Premasathian Nalinee, Larpparisuth Nuttasith, Skulratanasak Peenida, Vongwiwatana Attapong

机构信息

Division of Nephrology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Thailand.

出版信息

Front Med (Lausanne). 2022 Jul 8;9:869535. doi: 10.3389/fmed.2022.869535. eCollection 2022.

Abstract

BACKGROUND

Compared with other kidney replacement therapies, preemptive kidney transplantation (KT) provides better clinical outcomes, reduces mortality, and improves the quality of life of patients with end-stage kidney disease (ESKD). However, evidence related to the cost-effectiveness of preemptive living-related KT (LRKT) is limited, especially in low- and middle-income countries, such as Thailand. This study compared the cost-effectiveness of LRKT with those of non-preemptive KT strategies.

METHODS

Cost and clinical data were obtained from adult patients who underwent KT at Siriraj Hospital, Mahidol University, Thailand. A decision tree and Markov model were used to evaluate and compare the lifetime costs and health-related outcomes of LRKT with those of 2 KT strategies: non-preemptive LRKT and non-preemptive deceased donor KT (DDKT). The model's input parameters were sourced from the hospital's database and a systematic review. The primary outcome was incremental cost-effectiveness ratios (ICERs). Costs are reported in 2020 United States dollars (USD). One-way and probabilistic sensitivity analyses were performed.

RESULTS

Of 140 enrolled KT patients, 40 were preemptive LRKT recipients, 50 were non-preemptive LRKT recipients, and the rest were DDKT recipients. There were no significant differences in the baseline demographic data, complications, or rejection rates of the three groups of patients. The average costs per life year gained were $10,647 (preemptive LRKT), $11,708 (non-preemptive LRKT), and $11,486 (DDKT). The QALY gained of the preemptive option was 0.47 compared with the non-preemptive strategies. Preemptive LRKT was the best-buy strategy. The sensitivity analyses indicated that the model was robust. Within all varied ranges of parameters, preemptive LRKT remained cost-saving. The probability of preemptive LRKT being cost-saving was 79.4%. Compared with non-preemptive DDKT, non-preemptive LRKT was not cost-effective at the current Thai willingness-to-pay threshold of $5113/QALY gained.

CONCLUSIONS

Preemptive LRKT is a cost-saving strategy compared with non-preemptive KT strategies. Our findings should be considered during evidence-based policy development to promote preemptive LRKT among adults with ESKD in Thailand.

摘要

背景

与其他肾脏替代疗法相比,抢先肾移植(KT)可提供更好的临床结局,降低死亡率,并改善终末期肾病(ESKD)患者的生活质量。然而,与抢先活体亲属肾移植(LRKT)成本效益相关的证据有限,尤其是在泰国等低收入和中等收入国家。本研究比较了LRKT与非抢先肾移植策略的成本效益。

方法

成本和临床数据来自泰国玛希隆大学诗里拉吉医院接受肾移植的成年患者。使用决策树和马尔可夫模型来评估和比较LRKT与两种肾移植策略(非抢先LRKT和非抢先尸体供肾肾移植(DDKT))的终身成本和健康相关结局。模型的输入参数来自医院数据库和系统评价。主要结局是增量成本效益比(ICER)。成本以2020年美元(USD)报告。进行了单因素和概率敏感性分析。

结果

在140名登记的肾移植患者中,40名是抢先LRKT受者,50名是非抢先LRKT受者,其余是DDKT受者。三组患者的基线人口统计学数据、并发症或排斥率无显著差异。每获得一个生命年的平均成本分别为10,647美元(抢先LRKT)、11,708美元(非抢先LRKT)和11,486美元(DDKT)。与非抢先策略相比,抢先方案获得的质量调整生命年(QALY)为0.47。抢先LRKT是性价比最高的策略。敏感性分析表明模型稳健。在所有参数变化范围内,抢先LRKT仍具有成本节约优势。抢先LRKT具有成本节约优势的概率为79.4%。与非抢先DDKT相比,在泰国目前每获得一个QALY支付意愿阈值为5113美元的情况下,非抢先LRKT不具有成本效益。

结论

与非抢先肾移植策略相比,抢先LRKT是一种成本节约策略。在基于证据的政策制定过程中应考虑我们的研究结果,以在泰国ESKD成年患者中推广抢先LRKT。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c0be/9304573/eb97b69e8af3/fmed-09-869535-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验